Intravascular Chemical Sensors with Improved Biocompatiblity/Performance via Nitric Oxide Release
通过一氧化氮释放改善生物相容性/性能的血管内化学传感器
基本信息
- 批准号:9525342
- 负责人:
- 金额:$ 39.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-21 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAnti-inflammatoryArteriesBacteriaBindingBloodBlood CirculationBlood PlateletsBlood VesselsBlood gasBlood specimenCD47 geneCathetersCell AdhesionCellsChemicalsChemistryClinicalCritical CareCritical IllnessDetectionDevicesElectrolytesEndotheliumEnzymesExhibitsExposure toFamily suidaeFoundationsGenerationsGlucoseGoalsGrantHospitalsHourHumanHydrogen PeroxideImmobilizationImmuneImplantIn SituIn VitroInfectionInfection preventionInflammatoryInflammatory ResponseIntegral Membrane ProteinIntensive CareIntensive Care UnitsMeasurementMeasuresMicrobial BiofilmsMonitorNitric OxideOxygenPatient CarePatientsPediatric HospitalsPenicillaminePerformancePhasePhiladelphiaPhysiologicalPlatelet ActivationPolymersPolyurethanesProductionPropertyProteinsReceptor SignalingRecombinantsResearchResearch SupportRiskS-NitrosothiolsSHPS-1 proteinSheepSideSiliconesSolventsSterilizationSurfaceSwellingTechnologyTemperatureTestingThrombusTimeToxic effectTranslatingTranslationsUnited States National Institutes of HealthVeinsWorkanimal dataantimicrobialawakebactericidebiomaterial compatibilityclinical practicecostexperimental studyglucose sensorhealth care qualityhigh riskimplantable deviceimplanted sensorimprovedin vivoinnovationmacrophageminiaturizeneutrophilnovelpreventreal time monitoringreceptorresponsescaffoldscreeningsensorsensor technologysuccess
项目摘要
ABSTRACT
To date, efforts to develop clinically viable in vivo chemical sensors for real-time monitoring of blood gases,
electrolytes, glucose, lactate, etc. in critically ill hospital patients have been stymied by inaccurate analytical
results due to sensor biocompatibility problems (cell adhesion, thrombus formation, etc.) and a high risk of
infection. Our research over the past 15 years has been to explore and optimize the chemistry required to
fabricate in vivo chemical sensors that slowly release low levels of nitric oxide (NO). The local release of NO
mimics the chemistry that occurs at the inner walls of all healthy blood vessels (NO production by endothelium)
and by immune cells (macrophages, neutrophils) and is expected to greatly enhance the biocompatibility and
bactericidal properties of the intravascular sensors. This will lead to improved analytical performance of the
implanted sensors and less risk of infection. Indeed, results obtained with prior NIH support have clearly
demonstrated that in situ release of NO significantly reduces surface thrombus formation and improves the in
vivo analytical accuracy of intravascular oxygen and glucose sensors. Very recently, a completely new type of
NO releasing polymer material (S-nitrosothiol (RSNO) impregnated catheter tubing) has been developed that
possesses highly desirable long-term shelf stability, long-term NO release, ease of sterilization with ETO, and
low toxicity. We now wish to utilize this simple and low cost NO release chemistry to implement a new phase
of research that we anticipate will lead to translation of this technology to real-time sensor technology for the
intensive care units (ICU) at the end of the proposed 4-year project period. Our primary goal will be to assess
whether these new materials can be readily used to fabricate catheter type electrochemical sensors (for
oxygen, glucose, and lactate) that exhibit greatly enhanced in vivo analytical performance (in pigs and sheep).
In addition to NO release, we will also explore the potential advantages of combining the new RSNO-
impregnation chemistry with immobilized CD47 on the surface of the sensors. CD47 is a potent anti-
inflammatory/anti-platelet activation agent that binds to the SIRPα receptor on surfaces of many inflammatory
cells, including platelets. Optimal NO release and combined NO release/CD47 modified sensors for monitoring
oxygen (PO2), glucose, and lactate will first be evaluated side-by-side (vs. corresponding non-NO release
controls) in vivo within arteries and veins of anesthetized pigs (over 24 h period). The most promising
approach derived from this initial screening will then be tested in fully awake sheep over 10 d periods to prove
the enhanced analytical performance resulting from the antithrombotic/antimicrobial properties of this new
generation of implantable electrochemical sensors. The ability to reliably measure critical care analytes in
blood continuously at a patient's bedside is the “holy grail” for biomedical sensor technology, and this goal can
only be achieved when sensor performance is not compromised by biocompatibility and infection issues.
摘要
迄今为止,开发用于实时监测血气的临床上可行的体内化学传感器的努力,
电解质、葡萄糖、乳酸盐等在重症医院患者中的不准确分析
由于传感器生物相容性问题(细胞粘附、血栓形成等)导致的结果而且很有可能
感染我们在过去15年的研究一直在探索和优化所需的化学物质,
制造体内化学传感器,缓慢释放低水平的一氧化氮(NO)。当地释放NO
模拟所有健康血管内壁发生的化学反应(内皮细胞产生NO)
和免疫细胞(巨噬细胞、嗜中性粒细胞)的作用,并预期大大增强生物相容性,
血管内传感器的杀菌特性。这将导致改进的分析性能,
植入式传感器和更低的感染风险。事实上,在先前NIH支持下获得的结果显然
表明原位释放NO显著减少表面血栓形成,并改善血管内血栓形成。
血管内氧和葡萄糖传感器的体内分析准确性。最近,一种全新的
已经开发了释放NO的聚合物材料(S-亚硝基硫醇(RSNO)浸渍的导管),
具有非常理想的长期贮存稳定性、长期NO释放、易于用ETO灭菌,和
低毒性。我们现在希望利用这种简单且低成本的NO释放化学来实施新的阶段
我们预计将导致这项技术的翻译为实时传感器技术,
在拟议的4年项目期结束时,重症监护病房(ICU)。我们的首要目标是评估
这些新材料是否可以容易地用于制造导管型电化学传感器(用于
氧、葡萄糖和乳酸盐),其表现出极大增强的体内分析性能(在猪和羊中)。
除了NO的释放,我们还将探索结合新的RSNO-
浸渍化学与固定的CD 47在传感器的表面上。CD 47是一种有效的抗-
炎症/抗血小板活化剂,结合许多炎性细胞表面的SIRPα受体
细胞,包括血小板。最佳NO释放和组合NO释放/CD 47修饰传感器用于监测
首先将并排评估氧气(PO 2)、葡萄糖和乳酸盐(与相应的非NO释放相比
对照)在麻醉猪的动脉和静脉内体内(超过24小时)。最有前途的
然后,将在完全清醒的绵羊中进行10天以上的试验,以证明
由于这种新的抗血栓形成/抗微生物特性,
可植入电化学传感器的产生。能够可靠地测量重症监护分析物,
在病人床边连续采集血液是生物医学传感器技术的“圣杯”,这一目标可以
只有当传感器性能不受生物相容性和感染问题影响时才能实现。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK E MEYERHOFF其他文献
MARK E MEYERHOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK E MEYERHOFF', 18)}}的其他基金
Advanced Thromboresistant/Bactericidal Catheters via Electromodulated NO Release
通过电调节 NO 释放的先进抗血栓/杀菌导管
- 批准号:
9405609 - 财政年份:2017
- 资助金额:
$ 39.47万 - 项目类别:
Amperometric NO(g) Sensors with Improved Selectivity/Sensitivity for Biomedical Measurements
用于生物医学测量的具有更高选择性/灵敏度的电流型 NO(g) 传感器
- 批准号:
9068096 - 财政年份:2015
- 资助金额:
$ 39.47万 - 项目类别:
Amperometric NO(g) Sensors with Improved Selectivity/Sensitivity for Biomedical Measurements
用于生物医学测量的具有更高选择性/灵敏度的电流型 NO(g) 传感器
- 批准号:
8967508 - 财政年份:2015
- 资助金额:
$ 39.47万 - 项目类别:
Advanced Thromboresistant/Bactericidal Catheters via Electromodulated NO Release
通过电调节 NO 释放的先进抗血栓/杀菌导管
- 批准号:
8916211 - 财政年份:2014
- 资助金额:
$ 39.47万 - 项目类别:
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release
通过释放一氧化氮减少隧道式透析导管功能障碍
- 批准号:
9188634 - 财政年份:2013
- 资助金额:
$ 39.47万 - 项目类别:
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release
通过释放一氧化氮减少隧道式透析导管功能障碍
- 批准号:
8741962 - 财政年份:2013
- 资助金额:
$ 39.47万 - 项目类别:
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release
通过释放一氧化氮减少隧道式透析导管功能障碍
- 批准号:
8638515 - 财政年份:2013
- 资助金额:
$ 39.47万 - 项目类别:
Thromboresistant Polymers Via Catalytic Generation of NO
通过催化生成 NO 的抗血栓聚合物
- 批准号:
7644722 - 财政年份:2005
- 资助金额:
$ 39.47万 - 项目类别:
Thromboresistant Polymers via Catalytic Generation of NO
通过催化生成 NO 的抗血栓聚合物
- 批准号:
7407496 - 财政年份:2005
- 资助金额:
$ 39.47万 - 项目类别:
Thromboresistant Polymers Via Catalytic Generation of NO
通过催化生成 NO 的抗血栓聚合物
- 批准号:
8241135 - 财政年份:2005
- 资助金额:
$ 39.47万 - 项目类别:
相似海外基金
Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
- 批准号:
23K07659 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
- 批准号:
23K15705 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
- 批准号:
23K19490 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
- 批准号:
10697567 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
- 批准号:
10727765 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
- 批准号:
23K08467 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
- 批准号:
493138 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
- 批准号:
23K13905 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
- 批准号:
2223225 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别:
Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
- 批准号:
10651054 - 财政年份:2023
- 资助金额:
$ 39.47万 - 项目类别: